An observational study in Crohn Disease (CD), sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Central Hospital, Nancy, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Crohn Disease by Central Hospital, Nancy, France — 6 open to participants now, 7 under way, none of them phase 3. Crohn Disease · Central Hospital, Nancy, France.
Among the 17 studies in Crohn Disease by Central Hospital, Nancy, France, this one is the only one that started in 2026, is one of 7 observational ones, and was the 17th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →6 of the 17 studies in Crohn Disease by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:
Central Hospital, Nancy, France · Sites in France
Ages 18+ · Healthy volunteers
Central Hospital, Nancy, France · Sites in France
Ages 18+
Central Hospital, Nancy, France · Sites in France
Ages 18–65
Central Hospital, Nancy, France · Sites in France
Ages 18+ · Healthy volunteers
Central Hospital, Nancy, France · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 60 is below the median of 184 across 646 observational studies indexed under Crohn Disease.
Median enrollment 104 across the 10 interventional studies, 60 across the 7 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Central Hospital, Nancy, France is the lead sponsor of 801 studies on the registry; 188 are open to participants now.
3 of the studies in Crohn Disease by Central Hospital, Nancy, France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05254886Central Hospital, Nancy, FranceIdentification and Management of Comorbidities and Extra-intestinal Manifestations in Crohn's Disease: the NEMO Nurse-led Program | 2027-01-01 |
| NCT07413653Central Hospital, Nancy, FranceVirtual hIStology of Crohn's Disease Ex-vivo Resected Anatomical Lesions | 2027-10-01 |
| NCT03983473Central Hospital, Nancy, FranceIdentification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease. | 2027-11-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Crohn Disease by Central Hospital, Nancy, France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Crohn's disease is a chronic, incurable inflammatory bowel disease with an unpredictable course, characterized by alternating remission and inflammatory flares. Current follow-up strategies are poorly suited to early flare detection, leading to uncontrolled disease progression and complications. A major clinical challenge is distinguishing reversible inflammatory activity from irreversible intestinal fibrosis, as existing imaging techniques lack specificity. This study aims to perform comprehensive ex vivo multiparametric MRI, combined with biophysical measurements and histopathology, on resected intestinal specimens to precisely map inflammation and fibrosis and to validate in vivo MRI-derived biomarkers for personalized therapeutic decision-making.
Adults (≥18 years) diagnosed with Crohn's disease who are undergoing planned intestinal resection surgery at CHRU Nancy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- None
Patients with Crohn's disease undergoing planned intestinal resection surgery. Resected intestinal specimens will be analyzed ex vivo using multiparametric magnetic resonance imaging, biophysical measurements (mechanical and electrical properties), and histopathological examination. No experimental intervention is performed on participants beyond standard surgical care.
Ex vivo MRI assessment of intestinal biophysical properties - T2 relaxometry
Measurement of T2 relaxometry (ms) of resected intestinal tissue using ex vivo MRI.
Time frame: Baseline (J0): day of surgery
Ex vivo MRI assessment of intestinal biophysical properties - T1 relaxometry
Measurement of T1 relaxometry (ms) of resected intestinal tissue using ex vivo MRI.
Time frame: Baseline (J0): day of surgery
Ex vivo MRI assessment of intestinal electrical properties - conductivity
Measurement of tissue conductivity (S/m) using MR electrical properties tomography (MR-EPT).
Time frame: Baseline (J0): day of surgery
Ex vivo MRI assessment of intestinal electrical properties - permittivity
Measurement of tissue relative permittivity (unitless) using MR electrical properties tomography (MR-EPT).
Time frame: Baseline (J0): day of surgery
Ex vivo MRI assessment of intestinal mechanical properties - elastography
Measurement of tissue stiffness (kPa) using magnetic resonance elastography.
Time frame: Baseline (J0): day of surgery
Histopathological quantification of intestinal fibrosis - total area
Measurement of fibrotic area (mm²) on the entire histological section from the area of maximal stenosis.
Time frame: Baseline (J0): day of surgery
Histopathological quantification of intestinal inflammation - total area
Measurement of inflammatory area (mm²) on the entire histological section from the area of maximal stenosis.
Time frame: Baseline (J0): day of surgery
Association between ex vivo and in vivo MRI lesion characteristics
Correlation between lesion properties measured ex vivo and in vivo MRI parameters of the same lesions.
Time frame: Baseline (J0): day of surgery
Association between intestinal lesion characteristics and clinical events
Correlation between in vivo MRI-derived intestinal lesion characteristics and occurrence of clinical events (emergency visits for abdominal pain, hospitalizations for digestive causes, additional intestinal resection) within 12 months post-surgery.
Time frame: 12 months post-surgery
Started Sep 2026 (actual). Primary completion is estimated for Oct 2027, 12 months after the start.
Of 232 non-industry observational studies under Crohn Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 101. This study's planned 12 months is below that.
Counting every sponsor, half of 305 studies reached it within 41 months; a quarter within 29 and three quarters within 88.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Apr 2026 → Sep 2026, primary completion Apr 2027 → Oct 2027 and completion Apr 2028 → Oct 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →